Lataa...
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and...
Tallennettuna:
| Julkaisussa: | Blood |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Hematology
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5865231/ https://ncbi.nlm.nih.gov/pubmed/29330221 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-09-801498 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|